PubMed Health⌕ Search

PubMed · 89732

Human B cell function in a polyclonally induced plaque forming cell system. Cell triggering and immunoregulation.

Abstract

The use of a sensitive PFC assay against a specific antigenic determinant (SRBC) following polyclonal triggering of human lymphocytes has provided a unique insight into the complex mechanisms of triggering of human B cells. The system is under the strict regulation of a delicate balance between helper and suppressor influences reflecting in certain circumstances the activity of distinct subsets of immunoregulatory cells. Lymphoid cells in certain diseases characterized by disordered immunoregulation, when as system, may in effect be manifesting an abnormal expression of immunoregulatory mechanisms operable in normal immune responses. In vivo activation of lymphoid cells by PBAs may have an important role in disease states as well as in the subsequent in vitro expression of B cell function. Furthermore, it is quite possible that under certain circumstances some B cell responses which appear to be purely antigen-specific may be reflections of synergy between PBA substances and specific antigen. The use of PBAs as probes and sensitive PVC systems as assays has already proven fruitful in the dissection of the complex mechanisms of nonspecific B cell triggering in man and may indeed ultimately lead to an understanding of the mechanisms of specificity of immune reactivity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A S Fauci. 1979. Human B cell function in a polyclonally induced plaque forming cell system. Cell triggering and immunoregulation.. https://doi.org/10.1111/j.1600-065x.1979.tb00274.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗